Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
Healthcare
$3.72 +1.71%
+$0.06 today
- Market cap
- $284.14M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
52W Low $2.83High $15.74
Volume 0.63M
Average 1.78M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$60.06M
FY 2025 · Annual
Investing Cash Flow
$30.72M
FY 2025 · Annual
-4.7% YoYFinancing Cash Flow
$168.67M
FY 2025 · Annual
+6042.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Depreciation & Amortization | 2.52M | 2.41M | 2.17M | 1.59M | 1.39M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.07M | 13.35M | 14.8M | 14.55M | 12.47M |
| Change in Working Capital | (11.89M) | (3.09M) | (4.61M) | (4.25M) | 3.91M |
| Accounts Receivables | (500K) | 2.5M | (308K) | (1.56M) | 2.1M |
| Inventory | 1.25M | 0 | 0 | 0 | 0 |
| Accounts Payables | 973K | (1.18M) | (853K) | (1.59M) | 428K |
| Other Working Capital | (13.61M) | (4.42M) | (3.45M) | (1.1M) | 1.39M |
| Other Non-Cash Items | 673K | 152K | (5.99M) | (4.39M) | (2.95M) |
| Operating Cash Flow | (78.48M) | (97.05M) | (90.97M) | (2.22M) | (60.07M) |
| Capital Expenditures | (1.71M) | (1.96M) | (508K) | (278K) | (314K) |
| Acquisitions (Net) | 127.96M | (14.38M) | 0 | 0 | 0 |
| Purchases of Investments | (216.23M) | (151.15M) | (194.89M) | (178.59M) | (180.22M) |
| Sales of Investments | 88.28M | 165.53M | 158.71M | 211.1M | 211.25M |
| Other Investing Activities | (127.96M) | 14.38M | 0 | 0 | 0 |
| Investing Cash Flow | (129.67M) | 12.41M | (36.69M) | 32.23M | 30.72M |
| Debt Repayment | (18K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 182.86M | 80.8M | 117.35M | 2.75M | 168.67M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.67M | 3.52M | 777K | 0 | 0 |
| Financing Cash Flow | 186.51M | 84.32M | 118.12M | 2.75M | 168.67M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (21.64M) | (314K) | (9.54M) | 32.76M | 139.32M |
| Free Cash Flow | (80.19M) | (99.01M) | (91.47M) | (2.5M) | (60.38M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$74.9M
+ D&A$1.4M
+ Stock-Based Comp$12.5M
+ Deferred Tax$0
+ Working Capital$3.9M
- Other Non-Cash-$3.0M
= Operating Cash Flow-$60.1M
- Capex-$314.0K
= Free Cash Flow-$60.4M
Analysis
FY2025 free cash flow is -$60.4M. FCF conversion is 80.6% of net income. Operating cash flow was -$60.1M, with capex of -$314.0K. The largest bridge item is Stock-Based Comp at $12.5M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 425 | 425 filing | Nov 12, 2026 |
Does FULC generate free cash flow?
Fulcrum Therapeutics, Inc. (FULC) generated -$60.38M of free cash flow in fiscal 2025.
How much operating cash flow does FULC produce?
Operating cash flow was -$60.06M, before capital expenditures of $314,000.00.
Continue the stock analysis
Jump to another research area for this company.